This page has only limited features, please log in for full access.

Unclaimed
Jaeil Ahn
Department of Biostatistics, Bioinformatics, and Biomathematics Georgetown University

Honors and Awards

The user has no records in this section


Career Timeline

The user has no records in this section.


Short Biography

The user biography is not available.
Following
Followers
Co Authors
The list of users this user is following is empty.
Following: 0 users

Feed

Correspondence
Published: 25 August 2021 in American Journal of Hematology
Reads 0
Downloads 0

Patients with high-risk multiple myeloma (hrMM) relapse after autologous stem cell transplantation (ASCT) with a median progression free survival (PFS) of 8-14 months without lenalidomide maintenance and 24-39 months with lenalidomide maintenance. We hypothesized that Pembro-Rd will prolong PFS post-ASCT in patients with hrMM compared to historical controls. This Phase II study enrolled hrMM patients with primary objective to assess the efficacy of the combination of Pembro-Rd for a total of 2 cycles and then an additional 2 cycles without dexamethasone. There were 12 evaluable subjects, as enrollment was stopped after an FDA hold. With a median follow-up of 50.7 months, the median PFS was 27.7 months. The PFS rates at years 1 and 2 are 90.9% and 63.6%, respectively. The most common adverse events were neutropenia (grade 1-3), cough, diarrhea and constipation, all grade 1 or 2. The PFS rate with fixed duration therapy was comparable to that seen with continuous dose lenalidomide, potentially offering a new post-ASCT therapeutic strategy.

ACS Style

Noa Biran; Elli Gourna Paleoudis; Rena Feinman; David H. Vesole; Joshua Zenreich; Shuqi Wang; Jaeil Ahn; Meena Bansal; Scott Rowley; Michele Donato; Andrew L. Pecora; Joshua Richter; Palka Anand; Laura McBride; Kristin Ivanovski; Robert Korngold; David S. Siegel. Pembrolizumab, Lenalidomide and Dexamethasone Post Autologous Transplant in Patients with High‐Risk Multiple Myeloma. American Journal of Hematology 2021, 1 .

AMA Style

Noa Biran, Elli Gourna Paleoudis, Rena Feinman, David H. Vesole, Joshua Zenreich, Shuqi Wang, Jaeil Ahn, Meena Bansal, Scott Rowley, Michele Donato, Andrew L. Pecora, Joshua Richter, Palka Anand, Laura McBride, Kristin Ivanovski, Robert Korngold, David S. Siegel. Pembrolizumab, Lenalidomide and Dexamethasone Post Autologous Transplant in Patients with High‐Risk Multiple Myeloma. American Journal of Hematology. 2021; ():1.

Chicago/Turabian Style

Noa Biran; Elli Gourna Paleoudis; Rena Feinman; David H. Vesole; Joshua Zenreich; Shuqi Wang; Jaeil Ahn; Meena Bansal; Scott Rowley; Michele Donato; Andrew L. Pecora; Joshua Richter; Palka Anand; Laura McBride; Kristin Ivanovski; Robert Korngold; David S. Siegel. 2021. "Pembrolizumab, Lenalidomide and Dexamethasone Post Autologous Transplant in Patients with High‐Risk Multiple Myeloma." American Journal of Hematology , no. : 1.

Accepted manuscript
Published: 05 April 2021 in JNCI: Journal of the National Cancer Institute
Reads 0
Downloads 0
ACS Style

Jeanne S Mandelblatt; Xingtao Zhou; Brent J Small; Jaeil Ahn; Wanting Zhai; Tim Ahles; Martine Extermann; Deena Graham; Paul B Jacobsen; Heather Jim; Brenna C McDonald; Sunita K Patel; James C Root; Andrew J Saykin; Harvey Jay Cohen; Judith E Carroll. Response to Dekker, Stege, and Versteeg. JNCI: Journal of the National Cancer Institute 2021, 1 .

AMA Style

Jeanne S Mandelblatt, Xingtao Zhou, Brent J Small, Jaeil Ahn, Wanting Zhai, Tim Ahles, Martine Extermann, Deena Graham, Paul B Jacobsen, Heather Jim, Brenna C McDonald, Sunita K Patel, James C Root, Andrew J Saykin, Harvey Jay Cohen, Judith E Carroll. Response to Dekker, Stege, and Versteeg. JNCI: Journal of the National Cancer Institute. 2021; ():1.

Chicago/Turabian Style

Jeanne S Mandelblatt; Xingtao Zhou; Brent J Small; Jaeil Ahn; Wanting Zhai; Tim Ahles; Martine Extermann; Deena Graham; Paul B Jacobsen; Heather Jim; Brenna C McDonald; Sunita K Patel; James C Root; Andrew J Saykin; Harvey Jay Cohen; Judith E Carroll. 2021. "Response to Dekker, Stege, and Versteeg." JNCI: Journal of the National Cancer Institute , no. : 1.

Review
Published: 26 March 2021 in Toxicology
Reads 0
Downloads 0

The linear no-threshold (LNT) model has historically been the default assumption in assessing carcinogenic risk from arsenic ingestion based on epidemiological studies. This contrasts with the threshold model used in assessing carcinogenic risk from arsenic ingestion derived from toxicological investigations of experimental animals. We present here a review of our epidemiological work that has examined models that may better explain the human cancer risk from the ingestion of arsenic, particularly from low level exposures, than does the LNT model. While previous epidemiology studies have demonstrated increased risks of bladder, lung, and skin cancers at arsenic exposures of 200 ug/L or greater, we seek here to examine the dose-response patterns at lower exposure levels. These include ecological, case/control, and cohort designs. Methodologic issues include choice of continuous or stratified analysis of exposure data, search for sources of non-conformity or variability, and distinctions in water sources and geography. Multiple studies have yielded useful data-based models, including threshold models, hockey-stick models, and “J-shaped” linear-quadratic models. These models have found that increased cancer risk may only begin at specific arsenic exposure levels greater than zero. These results provide guidance in seeking toxicological explanations and public health reference levels.

ACS Style

Steven H. Lamm; Isabella J. Boroje; Hamid Ferdosi; Jaeil Ahn. A review of low-dose arsenic risks and human cancers. Toxicology 2021, 456, 152768 .

AMA Style

Steven H. Lamm, Isabella J. Boroje, Hamid Ferdosi, Jaeil Ahn. A review of low-dose arsenic risks and human cancers. Toxicology. 2021; 456 ():152768.

Chicago/Turabian Style

Steven H. Lamm; Isabella J. Boroje; Hamid Ferdosi; Jaeil Ahn. 2021. "A review of low-dose arsenic risks and human cancers." Toxicology 456, no. : 152768.

Research article
Published: 11 March 2021 in PLOS ONE
Reads 0
Downloads 0

HIV coinfection is associated with more rapid liver fibrosis progression in hepatitis C (HCV) infection. Recently, much work has been done to improve outcomes of liver disease and to identify targets for pharmacological intervention in coinfected patients. In this study, we analyzed clinical data of 1,858 participants from the Women’s Interagency HIV Study (WIHS) to characterize risk factors associated with changes in the APRI and FIB-4 surrogate measurements for advanced fibrosis. We assessed 887 non-synonymous single nucleotide variants (nsSNV) in a subset of 661 coinfected participants for genetic associations with changes in liver fibrosis risk. The variants utilized produced amino acid substitutions that either altered an N-linked glycosylation (NxS/T) sequon or mapped to a gene related to glycosylation processes. Seven variants were associated with an increased likelihood of liver fibrosis. The most common variant, ALPK2 rs3809973, was associated with liver fibrosis in HIV/HCV coinfected patients; individuals homozygous for the rare C allele displayed elevated APRI (0.61, 95% CI, 0.334 to 0.875) and FIB-4 (0.74, 95% CI, 0.336 to 1.144) relative to those coinfected women without the variant. Although warranting replication, ALPK2 rs3809973 may show utility to detect individuals at increased risk for liver disease progression.

ACS Style

Alec T. McIntosh; Renhuizi Wei; Jaeil Ahn; Brad E. Aouizerat; Seble G. Kassaye; Michael H. Augenbraun; Jennifer C. Price; Audrey L. French; Stephen J. Gange; Kathryn M. Anastos; Radoslav Goldman. A genomic variant of ALPK2 is associated with increased liver fibrosis risk in HIV/HCV coinfected women. PLOS ONE 2021, 16, e0247277 .

AMA Style

Alec T. McIntosh, Renhuizi Wei, Jaeil Ahn, Brad E. Aouizerat, Seble G. Kassaye, Michael H. Augenbraun, Jennifer C. Price, Audrey L. French, Stephen J. Gange, Kathryn M. Anastos, Radoslav Goldman. A genomic variant of ALPK2 is associated with increased liver fibrosis risk in HIV/HCV coinfected women. PLOS ONE. 2021; 16 (3):e0247277.

Chicago/Turabian Style

Alec T. McIntosh; Renhuizi Wei; Jaeil Ahn; Brad E. Aouizerat; Seble G. Kassaye; Michael H. Augenbraun; Jennifer C. Price; Audrey L. French; Stephen J. Gange; Kathryn M. Anastos; Radoslav Goldman. 2021. "A genomic variant of ALPK2 is associated with increased liver fibrosis risk in HIV/HCV coinfected women." PLOS ONE 16, no. 3: e0247277.

Journal article
Published: 27 January 2021 in JNCI Cancer Spectrum
Reads 0
Downloads 0

Background Cancer-related cognitive decline (CRCD) has been linked to apolipoprotein E (APOE) gene ε4 polymorphisms. APOE ε4 polymorphisms are also the strongest genetic risk for late-onset Alzheimer disease (AD), whereas ε2 polymorphisms protect against AD. However, the effects of ε2 polymorphisms on CRCD have not been evaluated. Methods We evaluated nonmetastatic breast cancer survivors (n = 427) and matched noncancer controls (n = 407) ages 60-98 years assessed presystemic therapy from August 2010 to December 2017 with annual follow-up to 24 months. Neuropsychological assessment measured attention, processing speed, executive function, and learning and memory. Linear mixed-effects models tested the effects of having an ε2 allele (vs none) on longitudinal cognitive domain z scores by treatment group (chemotherapy with or without hormonal therapy, hormonal therapy, and control) controlling for covariates; participants with ε2/ε4 genotype were excluded. Sensitivity analyses examined effects of other covariates and any ε4 positivity. Results There was an interaction with genotype for attention, processing speed, and executive functioning domain scores (Beta = 0.32, 95% confidence interval = 0.00 to 0.65); the chemotherapy group with an ε2 allele had higher scores at baseline and maintained higher scores over time compared with those without an ε2 allele, and this protective effect was not seen for other groups. There was no effect of ε2 on learning and memory domain scores. Conclusions APOE ε2 polymorphisms may protect against CRCD in older breast cancer survivors receiving chemotherapy. With replication, this information could be useful for survivorship care and informing future studies of possible links to AD and defining mechanisms of protection.

ACS Style

Kathleen Van Dyk; Xingtao Zhou; Brent J Small; Jaeil Ahn; Wanting Zhai; Tim Ahles; Deena Graham; Paul B Jacobsen; Heather Jim; Brenna C McDonald; Kelly Nudelman Holohan; Sunita K Patel; G William Rebeck; James C Root; Andrew J Saykin; Harvey Jay Cohen; Jeanne S Mandelblatt; Judith E Carroll. Protective Effects of APOE ε2 Genotype on Cognition in Older Breast Cancer Survivors: The Thinking and Living With Cancer Study. JNCI Cancer Spectrum 2021, 5, pkab013 .

AMA Style

Kathleen Van Dyk, Xingtao Zhou, Brent J Small, Jaeil Ahn, Wanting Zhai, Tim Ahles, Deena Graham, Paul B Jacobsen, Heather Jim, Brenna C McDonald, Kelly Nudelman Holohan, Sunita K Patel, G William Rebeck, James C Root, Andrew J Saykin, Harvey Jay Cohen, Jeanne S Mandelblatt, Judith E Carroll. Protective Effects of APOE ε2 Genotype on Cognition in Older Breast Cancer Survivors: The Thinking and Living With Cancer Study. JNCI Cancer Spectrum. 2021; 5 (2):pkab013.

Chicago/Turabian Style

Kathleen Van Dyk; Xingtao Zhou; Brent J Small; Jaeil Ahn; Wanting Zhai; Tim Ahles; Deena Graham; Paul B Jacobsen; Heather Jim; Brenna C McDonald; Kelly Nudelman Holohan; Sunita K Patel; G William Rebeck; James C Root; Andrew J Saykin; Harvey Jay Cohen; Jeanne S Mandelblatt; Judith E Carroll. 2021. "Protective Effects of APOE ε2 Genotype on Cognition in Older Breast Cancer Survivors: The Thinking and Living With Cancer Study." JNCI Cancer Spectrum 5, no. 2: pkab013.

Journal article
Published: 23 January 2021 in JNCI: Journal of the National Cancer Institute
Reads 0
Downloads 0

Background We evaluated deficit accumulation and how deficits affected cognition and physical activity among breast cancer survivors and non-cancer controls. Methods Newly diagnosed nonmetastatic survivors (n = 353) and matched non-cancer controls (n = 355) ages 60-98 years without neurological impairments were assessed presystemic therapy (or at enrollment for controls) from August 2010 to December 2016 and followed for 36 months. Scores on a 42-item index were analyzed in growth-mixture models to determine deficit accumulation trajectories separately and combined for survivors and controls. Multilevel models tested associations between trajectory and cognition (FACT-Cog and neuropsychological tests) and physical activity (IPAQ-SF) for survivors and controls. Results Deficit accumulation scores were in the robust range, but survivors had higher scores (95% confidence intervals [CI]) than controls at 36 months (0.18, 95% CI = 0.16 to 0.19, vs 0.16, 95% CI = 0.14 to 0.17; P = .001), and averages included diverse deficit trajectories. Survivors who were robust but became frailer (8.8%) had similar baseline characteristics to those remaining robust (76.2%) but experienced a 9.6-point decline self-reported cognition (decline of 9.6 vs 3.2 points; P = .04) and a 769 MET minutes per week decline in physical activity (P < .001). Survivors who started and remained prefrail (15.0%) had self-reported and objective cognitive problems. At baseline, frail controls (9.5%) differed from robust controls (83.7%) on deficits and self-reported cognition (P < .001). Within combined trajectories, frail survivors had more sleep disturbances than frail controls (48.6% [SD = 17.4%] vs 25.0% [SD = 8.2%]; P = .05). Conclusions Most survivors and controls remained robust, and there were similar proportions on a frail trajectory. However, there were differences in deficit patterns between survivors and controls. Survivor deficit accumulation trajectory was associated with patient-reported outcomes. Additional research is needed to understand how breast cancer and its treatments affect deficit accumulation.

ACS Style

Jeanne S Mandelblatt; Xingtao Zhou; Brent J Small; Jaeil Ahn; Wanting Zhai; Tim Ahles; Martine Extermann; Deena Graham; Paul B Jacobsen; Heather Jim; Brenna C McDonald; Sunita J Patel; James C Root; Andrew J Saykin; Harvey Jay Cohen; Judith E Carroll. Deficit Accumulation Frailty Trajectories of Older Breast Cancer Survivors and Non-Cancer Controls: The Thinking and Living With Cancer Study. JNCI: Journal of the National Cancer Institute 2021, 113, 1053 -1064.

AMA Style

Jeanne S Mandelblatt, Xingtao Zhou, Brent J Small, Jaeil Ahn, Wanting Zhai, Tim Ahles, Martine Extermann, Deena Graham, Paul B Jacobsen, Heather Jim, Brenna C McDonald, Sunita J Patel, James C Root, Andrew J Saykin, Harvey Jay Cohen, Judith E Carroll. Deficit Accumulation Frailty Trajectories of Older Breast Cancer Survivors and Non-Cancer Controls: The Thinking and Living With Cancer Study. JNCI: Journal of the National Cancer Institute. 2021; 113 (8):1053-1064.

Chicago/Turabian Style

Jeanne S Mandelblatt; Xingtao Zhou; Brent J Small; Jaeil Ahn; Wanting Zhai; Tim Ahles; Martine Extermann; Deena Graham; Paul B Jacobsen; Heather Jim; Brenna C McDonald; Sunita J Patel; James C Root; Andrew J Saykin; Harvey Jay Cohen; Judith E Carroll. 2021. "Deficit Accumulation Frailty Trajectories of Older Breast Cancer Survivors and Non-Cancer Controls: The Thinking and Living With Cancer Study." JNCI: Journal of the National Cancer Institute 113, no. 8: 1053-1064.

Multicenter study
Published: 14 January 2021 in BMC Infectious Diseases
Reads 0
Downloads 0

Background Hydroxychloroquine has not been associated with improved survival among hospitalized COVID-19 patients in the majority of observational studies and similarly was not identified as an effective prophylaxis following exposure in a prospective randomized trial. We aimed to explore the role of hydroxychloroquine therapy in mildly symptomatic patients diagnosed in the outpatient setting. Methods We examined the association between outpatient hydroxychloroquine exposure and the subsequent progression of disease among mildly symptomatic non-hospitalized patients with documented SARS-CoV-2 infection. The primary outcome assessed was requirement of hospitalization. Data was obtained from a retrospective review of electronic health records within a New Jersey USA multi-hospital network. We compared outcomes in patients who received hydroxychloroquine with those who did not applying a multivariable logistic model with propensity matching. Results Among 1274 outpatients with documented SARS-CoV-2 infection 7.6% were prescribed hydroxychloroquine. In a 1067 patient propensity matched cohort, 21.6% with outpatient exposure to hydroxychloroquine were hospitalized, and 31.4% without exposure were hospitalized. In the primary multivariable logistic regression analysis with propensity matching there was an association between exposure to hydroxychloroquine and a decreased rate of hospitalization from COVID-19 (OR 0.53; 95% CI, 0.29, 0.95). Sensitivity analyses revealed similar associations. QTc prolongation events occurred in 2% of patients prescribed hydroxychloroquine with no reported arrhythmia events among those with data available. Conclusions In this retrospective observational study of SARS-CoV-2 infected non-hospitalized patients hydroxychloroquine exposure was associated with a decreased rate of subsequent hospitalization. Additional exploration of hydroxychloroquine in this mildly symptomatic outpatient population is warranted.

ACS Style

Andrew Ip; Jaeil Ahn; Yizhao Zhou; Andre H. Goy; Eric Hansen; Andrew L. Pecora; Brittany A. Sinclaire; Urszula Bednarz; Michael Marafelias; Ihor S. Sawczuk; Joseph P. Underwood Iii; David M. Walker; Rajiv Prasad; Robert L. Sweeney; Marie G. Ponce; Samuel La Capra; Frank J. Cunningham; Arthur G. Calise; Bradley L. Pulver; Dominic Ruocco; Greggory E. Mojares; Michael P. Eagan; Kristy L. Ziontz; Paul Mastrokyriakos; Stuart L. Goldberg. Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study. BMC Infectious Diseases 2021, 21, 1 -12.

AMA Style

Andrew Ip, Jaeil Ahn, Yizhao Zhou, Andre H. Goy, Eric Hansen, Andrew L. Pecora, Brittany A. Sinclaire, Urszula Bednarz, Michael Marafelias, Ihor S. Sawczuk, Joseph P. Underwood Iii, David M. Walker, Rajiv Prasad, Robert L. Sweeney, Marie G. Ponce, Samuel La Capra, Frank J. Cunningham, Arthur G. Calise, Bradley L. Pulver, Dominic Ruocco, Greggory E. Mojares, Michael P. Eagan, Kristy L. Ziontz, Paul Mastrokyriakos, Stuart L. Goldberg. Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study. BMC Infectious Diseases. 2021; 21 (1):1-12.

Chicago/Turabian Style

Andrew Ip; Jaeil Ahn; Yizhao Zhou; Andre H. Goy; Eric Hansen; Andrew L. Pecora; Brittany A. Sinclaire; Urszula Bednarz; Michael Marafelias; Ihor S. Sawczuk; Joseph P. Underwood Iii; David M. Walker; Rajiv Prasad; Robert L. Sweeney; Marie G. Ponce; Samuel La Capra; Frank J. Cunningham; Arthur G. Calise; Bradley L. Pulver; Dominic Ruocco; Greggory E. Mojares; Michael P. Eagan; Kristy L. Ziontz; Paul Mastrokyriakos; Stuart L. Goldberg. 2021. "Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study." BMC Infectious Diseases 21, no. 1: 1-12.

Journal article
Published: 01 January 2021 in Annals of Surgical Treatment and Research
Reads 0
Downloads 0

Gastrectomy for elderly patients can significantly deteriorate the health-related quality of life (HRQoL). There was no report comparing HRQoL of elderly patients with young patients after gastrectomy for gastric cancer. This study assessed the differences in the changes of HRQoL at one year after gastrectomy according to age. From May 2014 to Feb 2016, we prospectively enrolled patients undergoing gastrectomy for gastric cancer. They completed the European Organization for Research and Treatment of Cancer and gastric questionnaires preoperatively and at postoperative 1, 3, 6, 9, and 12 months. We included 57 elderly patients (≥70 years old) and 74 younger patients. The elderly had similar demographic, surgical, and pathological characteristics with young patients except that elderly had more comorbidity, laparoscopic gastrectomies, and lesser postoperative chemotherapy. One month after gastrectomy, the score of global health status/quality of life, physical, role, and social functioning were significantly impaired in elderly patients. Among them, physical and role functioning were more impaired than those of young patients. The scores of physical functioning, role functioning, cognitive functioning, and social functioning were not fully recovered till 1 year after surgery. There was a significant age group difference in the changes in physical function over the 1-year follow-up. Elderly patients' global health status/quality of life and social functioning significantly decreased at postoperative 1 month and recovered by 6 months after gastrectomy. There was a significant age-specific difference in physical functioning throughout the 1-year follow-up. Surgeons need to pay more attention to recovery of the elderly patients' HRQoL after gastrectomy.

ACS Style

Dong-Seok Han; Jaeil Ahn; Hye Seong Ahn. Are the elderly patient's changes in the health-related quality of life one year after gastrectomy for stomach cancer different from those in young patients? Annals of Surgical Treatment and Research 2021, 100, 8 -17.

AMA Style

Dong-Seok Han, Jaeil Ahn, Hye Seong Ahn. Are the elderly patient's changes in the health-related quality of life one year after gastrectomy for stomach cancer different from those in young patients? Annals of Surgical Treatment and Research. 2021; 100 (1):8-17.

Chicago/Turabian Style

Dong-Seok Han; Jaeil Ahn; Hye Seong Ahn. 2021. "Are the elderly patient's changes in the health-related quality of life one year after gastrectomy for stomach cancer different from those in young patients?" Annals of Surgical Treatment and Research 100, no. 1: 8-17.

Preprint content
Published: 27 October 2020
Reads 0
Downloads 0

Background: Life expectancy can be estimated accurately from a cohort of individuals born in the same year and followed from birth to death. Due to the difficult and time-consuming nature of following a cohort prospectively, life expectancy is often assessed based on death data, which may lead to potentially biased estimates. This is more likely to be a problem in rare diseases such as Morquio syndrome A. Method: To investigate how accurate the estimation of life expectancy is using death data, we simulate the survival of individuals with Morquio syndrome A under four different survival scenarios. In each scenario, we estimate the mean and median survival times within a defined period and compare them with the true life expectancy. Results: When life expectancy is constant during the entire period, using death data does not result in a biased estimate of life expectancy. However, when life expectancy increases during the follow-up period, using only death data leads to a substantial underestimation of life expectancy. Conclusion: Life expectancy can change over time, along with changes in the environment and/or biomedical innovation. When the life expectancy is increasing --- as is often expected to be the case in rare diseases --- estimating it based on contemporary death data will result in a downward bias. Therefore, it is crucial to understand how estimates of life expectancy are obtained and to interpret them in an appropriate context, and to assess estimation methods within a sensitivity analysis framework, similar to the simulations performed herein.

ACS Style

Xue Yin; Jaeil Ahn; Simina Maria Boca. Understanding bias when estimating life expectancy from age at death: A simulation approach applied to Morquio Syndrome A. 2020, 1 .

AMA Style

Xue Yin, Jaeil Ahn, Simina Maria Boca. Understanding bias when estimating life expectancy from age at death: A simulation approach applied to Morquio Syndrome A. . 2020; ():1.

Chicago/Turabian Style

Xue Yin; Jaeil Ahn; Simina Maria Boca. 2020. "Understanding bias when estimating life expectancy from age at death: A simulation approach applied to Morquio Syndrome A." , no. : 1.

Original article
Published: 03 October 2020 in Journal of Genetic Counseling
Reads 0
Downloads 0

Bilateral salpingo‐oophorectomy (BSO) is a risk management approach with strong evidence of mortality reduction for women with germline mutations in the tumor suppressor genes BRCA1 and BRCA2 (BRCA1/2). Few studies to date have evaluated uptake of BSO in women from diverse racial and ethnic backgrounds who carry BRCA1/2 mutations. The objective of the UPTAKE study was to explore rates and predictors of risk‐reducing BSO among Latinas affected and unaffected with breast cancer who had a deleterious BRCA1/2 mutation. We recruited 100 Latina women with deleterious BRCA1/2 mutations from community hospitals, academic health systems, community, and advocacy organizations. Women completed interviews in Spanish or English. We obtained copies of genetic test reports for participants who provided signed medical release. After performing threefold cross‐validation LASSO for variable selection, we used multiple logistic regression to identify demographic and clinical predictors of BSO. Among 100 participants, 68 had undergone BSO at the time of interview. Of these 68, 35 were US‐born (61% of all US‐born participants) and 33 were not (77% of the non‐US‐born participants). Among Latinas with BRCA1/2 mutations, older age (p = 0.004), personal history of breast cancer (p = 0.003), higher income (p = 0.002), and not having a full‐time job (p = 0.027) were identified as variables significantly associated with uptake of BSO. Results suggest a high rate of uptake of risk‐reducing BSO among a sample of Latinas with BRCA1/2 mutations living in the US. We document factors associated with BSO uptake in a diverse sample of women. Relevant to genetic counseling, our findings identify possible targets for supporting Latinas’ decision‐making about BSO following receipt of a positive BRCA1/2 test.

ACS Style

Filipa Lynce; Ilana Schlam; Xue Geng; Beth N. Peshkin; Sue Friedman; Julie Dutil; Zeina Nahleh; Claudia Campos; Charité Ricker; Patricia Rodriguez; Neelima Denduluri; Jaeil Ahn; Claudine Isaacs; Kristi D. Graves. BRCA1/2 mutations and risk‐reducing bilateral salpingo‐oophorectomy among Latinas: The UPTAKE study. Journal of Genetic Counseling 2020, 1 .

AMA Style

Filipa Lynce, Ilana Schlam, Xue Geng, Beth N. Peshkin, Sue Friedman, Julie Dutil, Zeina Nahleh, Claudia Campos, Charité Ricker, Patricia Rodriguez, Neelima Denduluri, Jaeil Ahn, Claudine Isaacs, Kristi D. Graves. BRCA1/2 mutations and risk‐reducing bilateral salpingo‐oophorectomy among Latinas: The UPTAKE study. Journal of Genetic Counseling. 2020; ():1.

Chicago/Turabian Style

Filipa Lynce; Ilana Schlam; Xue Geng; Beth N. Peshkin; Sue Friedman; Julie Dutil; Zeina Nahleh; Claudia Campos; Charité Ricker; Patricia Rodriguez; Neelima Denduluri; Jaeil Ahn; Claudine Isaacs; Kristi D. Graves. 2020. "BRCA1/2 mutations and risk‐reducing bilateral salpingo‐oophorectomy among Latinas: The UPTAKE study." Journal of Genetic Counseling , no. : 1.

Other
Published: 29 September 2020
Reads 0
Downloads 0

HIV coinfection is associated with more rapid liver fibrosis progression in hepatitis C (HCV) infection. Recently, much work has been done to improve outcomes of liver disease and to identify targets for pharmacological intervention in coinfected patients. In this study, we analyzed clinical data of 1,858 participants from the Women’s Interagency HIV Study (WIHS) to characterize risk factors associated with changes in the APRI and FIB-4 surrogate measurements for advanced fibrosis. We assessed 887 non-synonymous single nucleotide variants (nsSNV) in a subset of 661 coinfected participants for genetic associations with changes in liver fibrosis risk. The variants utilized produced amino acid substitutions that either altered an N-linked glycosylation (NxS/T) sequon or mapped to a gene related to glycosylation processes. Seven variants were associated with an increased likelihood of liver fibrosis. The most common variant, ALPK2 rs3809973, was associated with liver fibrosis in HIV/HCV coinfected patients; individuals homozygous for the rare C allele displayed elevated APRI (0.61, 95% CI, 0.334 to 0.875) and FIB-4 (0.74, 95% CI, 0.336 to 1.144) relative to those coinfected women without the variant. Although warranting replication, ALPK2 rs3809973 may show utility to detect individuals at increased risk for liver disease progression.

ACS Style

Alec T. McIntosh; Renhuizi Wei; Jaeil Ahn; Brad E. Aouizerat; Seble G. Kassaye; Michael H. Augenbraun; Jennifer C. Price; Audrey L. French; Stephen J. Gange; Kathryn M. Anastos; Radoslav Goldman. A genomic variant of ALPK2 is associated with increased liver fibrosis risk in HIV/HCV coinfected women. 2020, 1 .

AMA Style

Alec T. McIntosh, Renhuizi Wei, Jaeil Ahn, Brad E. Aouizerat, Seble G. Kassaye, Michael H. Augenbraun, Jennifer C. Price, Audrey L. French, Stephen J. Gange, Kathryn M. Anastos, Radoslav Goldman. A genomic variant of ALPK2 is associated with increased liver fibrosis risk in HIV/HCV coinfected women. . 2020; ():1.

Chicago/Turabian Style

Alec T. McIntosh; Renhuizi Wei; Jaeil Ahn; Brad E. Aouizerat; Seble G. Kassaye; Michael H. Augenbraun; Jennifer C. Price; Audrey L. French; Stephen J. Gange; Kathryn M. Anastos; Radoslav Goldman. 2020. "A genomic variant of ALPK2 is associated with increased liver fibrosis risk in HIV/HCV coinfected women." , no. : 1.

Other
Published: 25 August 2020
Reads 0
Downloads 0

Background Hydroxychloroquine has not been associated with improved survival among hospitalized COVID-19 patients in the majority of observational studies and similarly was not identified as an effective prophylaxis following exposure in a prospective randomized trial. We aimed to explore the role of hydroxychloroquine therapy in mildly symptomatic patients diagnosed in the outpatient setting. Methods We examined the association between outpatient hydroxychloroquine exposure and the subsequent progression of disease among mildly symptomatic non-hospitalized patients with documented SARS-CoV-2 infection. The primary outcome assessed was requirement of hospitalization. Data was obtained from a retrospective review of electronic health records within a New Jersey USA multi-hospital network. We compared outcomes in patients who received hydroxychloroquine with those who did not applying a multivariable logistic model with propensity matching. Results Among 1274 outpatients with documented SARS-CoV-2 infection 7.6% were prescribed hydroxychloroquine. In a 1067 patient propensity matched cohort, 21.6% with outpatient exposure to hydroxychloroquine were hospitalized, and 31.4% without exposure were hospitalized. In the primary multivariable logistic regression analysis with propensity matching there was an association between exposure to hydroxychloroquine and a decreased rate of hospitalization from COVID-19 (OR 0.53; 95% CI, 0.29, 0.95). Sensitivity analyses revealed similar associations. QTc prolongation events occurred in 2% of patients prescribed hydroxychloroquine with no reported arrhythmia events among those with data available. Conclusions In this retrospective observational study of SARS-CoV-2 infected non-hospitalized patients hydroxychloroquine exposure was associated with a decreased rate of subsequent hospitalization. Additional exploration of hydroxychloroquine in this mildly symptomatic outpatient population is warranted. Lay Summary In this observational study of 1,274 COVID-19 patients, hydroxychloroquine given as an outpatient treatment was associated with a 47% reduction in the hazard of hospitalization. Adverse events were not increased (2% QTc prolongation events, 0% arrhythmias). Further validation is required. Use of hydroxychloroquine to treat COVID-19 in the outpatient setting should be reserved for a clinical trial or after discussion with a physician regarding risks and benefits.

ACS Style

Andrew Ip; Jaeil Ahn; Yizhao Zhou; Andre H. Goy; Eric Hansen; Andrew L Pecora; Brittany A Sinclaire; Urszula Bednarz; Michael Marafelias; Shivam Mathura; Ihor S Sawczuk; Joseph P. Underwood; David M. Walker; Rajiv Prasad; Robert L. Sweeney; Marie G. Ponce; Samuel La Capra; Frank J. Cunningham; Arthur G. Calise; Bradley L. Pulver; Dominic Ruocco; Greggory E. Mojares; Michael P. Eagan; Kristy L. Ziontz; Paul Mastrokyriakos; Stuart L Goldberg. Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center observational study. 2020, 1 .

AMA Style

Andrew Ip, Jaeil Ahn, Yizhao Zhou, Andre H. Goy, Eric Hansen, Andrew L Pecora, Brittany A Sinclaire, Urszula Bednarz, Michael Marafelias, Shivam Mathura, Ihor S Sawczuk, Joseph P. Underwood, David M. Walker, Rajiv Prasad, Robert L. Sweeney, Marie G. Ponce, Samuel La Capra, Frank J. Cunningham, Arthur G. Calise, Bradley L. Pulver, Dominic Ruocco, Greggory E. Mojares, Michael P. Eagan, Kristy L. Ziontz, Paul Mastrokyriakos, Stuart L Goldberg. Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center observational study. . 2020; ():1.

Chicago/Turabian Style

Andrew Ip; Jaeil Ahn; Yizhao Zhou; Andre H. Goy; Eric Hansen; Andrew L Pecora; Brittany A Sinclaire; Urszula Bednarz; Michael Marafelias; Shivam Mathura; Ihor S Sawczuk; Joseph P. Underwood; David M. Walker; Rajiv Prasad; Robert L. Sweeney; Marie G. Ponce; Samuel La Capra; Frank J. Cunningham; Arthur G. Calise; Bradley L. Pulver; Dominic Ruocco; Greggory E. Mojares; Michael P. Eagan; Kristy L. Ziontz; Paul Mastrokyriakos; Stuart L Goldberg. 2020. "Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center observational study." , no. : 1.

Journal article
Published: 04 February 2020 in International Journal of Environmental Research and Public Health
Reads 0
Downloads 0

Background: Although inorganic arsenic in drinking water at high levels (100s–1000s μg/L [ppb]) increases cancer risk (skin, bladder, lung, and possibly prostate), the evidence at lower levels is limited. Methods: We conducted an ecologic analysis of the dose-response relationship between prostate cancer incidence and low arsenic levels in drinking water in a large study of U.S. counties (N = 710). County arsenic levels were <200 ug/L with median <100 ug/L and dependency greater than 10%. Groundwater well usage, water arsenic levels, prostate cancer incidence rates (2009–2013), and co-variate data were obtained from various U.S. governmental agencies. Poisson and negative-binomial regression analyses and stratified analysis were performed. Results: The best fitting polynomial analysis yielded a J-shaped linear-quadratic model. Linear and quadratic terms were significant (p < 0.001) in the Poisson model, and the quadratic term was significant (p < 0.05) in the negative binomial model. This model indicated a decreasing risk of prostate cancer with increasing arsenic level in the low range and increasing risk above. Conclusions: This study of prostate cancer incidence in US counties with low levels of arsenic in their well-water arsenic levels finds a j-shaped model with decreasing risk at very low levels and increasing risk at higher levels.

ACS Style

Jaeil Ahn; Isabella J. Boroje; Hamid Ferdosi; Zachary J. Kramer; Steven H. Lamm. Prostate Cancer Incidence in U.S. Counties and Low Levels of Arsenic in Drinking Water. International Journal of Environmental Research and Public Health 2020, 17, 960 .

AMA Style

Jaeil Ahn, Isabella J. Boroje, Hamid Ferdosi, Zachary J. Kramer, Steven H. Lamm. Prostate Cancer Incidence in U.S. Counties and Low Levels of Arsenic in Drinking Water. International Journal of Environmental Research and Public Health. 2020; 17 (3):960.

Chicago/Turabian Style

Jaeil Ahn; Isabella J. Boroje; Hamid Ferdosi; Zachary J. Kramer; Steven H. Lamm. 2020. "Prostate Cancer Incidence in U.S. Counties and Low Levels of Arsenic in Drinking Water." International Journal of Environmental Research and Public Health 17, no. 3: 960.

Articles
Published: 24 July 2019 in Journal of Applied Statistics
Reads 0
Downloads 0

Batched data is a type of data where each observed data value is the sum of a number of grouped (batched) latent ones obtained under different conditions. Batched data arises in various practical backgrounds and is often found in social studies and management sector. The analysis of such data is analytically challenging due to its structural complexity. In this article, we describe how to analyze batched service time data, estimate the mean and variance of each batch that are latent. We in particular focus on the situation when the observed total time includes an unknown proportion of non-service time. To address this problem, we propose a Gaussian model for efficiency as well as a semi-parametric kernel density model for robustness. We evaluate the performance of both proposed methods through simulation studies and then applied our methods to analyze a batched data.

ACS Style

Xueying Wang; Chunxiao Zhou; Kepher Makambi; Ao Yuan; Jaeil Ahn. Analysis of batched service time data using Gaussian and semi-parametric kernel models. Journal of Applied Statistics 2019, 47, 524 -540.

AMA Style

Xueying Wang, Chunxiao Zhou, Kepher Makambi, Ao Yuan, Jaeil Ahn. Analysis of batched service time data using Gaussian and semi-parametric kernel models. Journal of Applied Statistics. 2019; 47 (3):524-540.

Chicago/Turabian Style

Xueying Wang; Chunxiao Zhou; Kepher Makambi; Ao Yuan; Jaeil Ahn. 2019. "Analysis of batched service time data using Gaussian and semi-parametric kernel models." Journal of Applied Statistics 47, no. 3: 524-540.

Research article
Published: 11 July 2019 in PLOS ONE
Reads 0
Downloads 0

Health disparities are commonplace and of broad interest to policy makers, but are also challenging to measure and communicate. The Health Disparity Calculator software (HD*Calc, v1.2.4) offers Monte Carlo simulation (MCS)-based confidence interval (CI) estimation of eleven disparity measures. The MCS approach provides accurate CI estimation, except when data are scarce (e.g., rare cancers). To address sparse data challenges to CI estimation, we propose two solutions: 1) employing the gamma distribution in the MCS and 2) utilizing a zero-inflated Poisson estimate for Poisson sampling in simulation experiments. We evaluate each solution through simulation studies using female breast, female brain, lung, and cervical cancer data from the Surveillance, Epidemiology, and End Results (SEER) program. We compare the coverage probabilities (CPs) of eleven health disparity measures based on simulated datasets. The truncated normal distribution implemented in the MCS with the standard Poisson samples (the default setting of HD*Calc) leads to less-than-optimal coverage probabilities (<95%). When both the gamma distribution and the estimated mean from the zero-inflated Poisson are used for the MCS, the coverage probabilities are close to the nominal level of 95%. Simulation studies also demonstrate that collapsing age categories for better CI estimation is not a pragmatic solution.

ACS Style

Jaeil Ahn; Sam Harper; Mandi Yu; Eric J. Feuer; Benmei Liu. Improved Monte Carlo methods for estimating confidence intervals for eleven commonly used health disparity measures. PLOS ONE 2019, 14, e0219542 .

AMA Style

Jaeil Ahn, Sam Harper, Mandi Yu, Eric J. Feuer, Benmei Liu. Improved Monte Carlo methods for estimating confidence intervals for eleven commonly used health disparity measures. PLOS ONE. 2019; 14 (7):e0219542.

Chicago/Turabian Style

Jaeil Ahn; Sam Harper; Mandi Yu; Eric J. Feuer; Benmei Liu. 2019. "Improved Monte Carlo methods for estimating confidence intervals for eleven commonly used health disparity measures." PLOS ONE 14, no. 7: e0219542.

Journal article
Published: 11 July 2019 in Statistical Methods in Medical Research
Reads 0
Downloads 0

Health-related quality of life consists of multi-dimensional measurements of physical and mental health domains. Health-related quality of life is often followed up to evaluate efficacy of treatments in clinical studies. During the follow-up period, a missing data problem inevitably arises. When missing data occur for reasons related to poor health-related quality of life, a complete-case only analysis can lead to invalid inferences. We propose a Bayesian approach to analyze longitudinal moderate to high-dimensional multivariate outcome data in the presence of non-ignorable missing data. To account for non-ignorable missing data, we employ a selection model for the joint likelihood factorization where we apply Bayesian spike and slab variable selection in the missing data mechanism to detect informative factors among multiple outcomes. We model the relationship between multiple outcomes and covariates using linear mixed effects models where multiple outcome correlations are captured by a hierarchical structure. We conduct simulation studies to evaluate the performance of the proposed method compared with the conventional last observation carried forward approach. We use a motivating example that originates from a longitudinal study of quality of life in gastric cancer patients who underwent distal gastrectomy. In this application, we demonstrate that our proposed method can offer efficiency gain in the marginal associations and provide the associations between outcomes and the absence of patients' information.

ACS Style

Jaeil Ahn; Hye Seong Ahn. Bayesian analysis of longitudinal quality of life measures with informative missing data using a selection model. Statistical Methods in Medical Research 2019, 29, 1354 -1367.

AMA Style

Jaeil Ahn, Hye Seong Ahn. Bayesian analysis of longitudinal quality of life measures with informative missing data using a selection model. Statistical Methods in Medical Research. 2019; 29 (5):1354-1367.

Chicago/Turabian Style

Jaeil Ahn; Hye Seong Ahn. 2019. "Bayesian analysis of longitudinal quality of life measures with informative missing data using a selection model." Statistical Methods in Medical Research 29, no. 5: 1354-1367.

Journal article
Published: 22 May 2019 in BMC Medical Education
Reads 0
Downloads 0

Student physicians are particularly prone to high rates of poor mental and physical quality of life, including depression, anxiety, and fatigue. We prospectively tested whether a structured, theory-based executive/life coaching program tailored to first year medical students in the United States was feasible, tolerable, and would be recommended by participants. Secondary goals included impact on coaching goals, resilience, and perceived stress. This single-arm intervention study evaluated a program of two group and two private coaching sessions during the first year, second semester of the Georgetown University School of Medicine Class of 2019. Survey data (global and tailored questions, Connor-Davidson resilience scale, Friedricksson-Larsson stress question) were collected from participants at baseline and post-intervention. 37/40 students completed the intervention; 32 completed the pre-post surveys. Most (32/37) were willing to recommend the program (16/37 were very willing) and 29/37 recommended inclusion in the curriculum. Responses to tailored questions showed significant increases in self-efficacy regarding stress management (p < 0.001); increased awareness of thoughts about stress and management of those thoughts (p = 0.05). Reported improvements in time management (p = 0.10) and energy for relationships and school (p = 0.089) did not achieve significance. Global resilience rating was not different (p = 0.186), but significant changes were seen in control (p = 0.029) and spiritual influence (p = 0.005) factors. Although the Friedricksson-Larsson item was not significantly different (p = 0.242), 40.6% of participants reported decreased stress and 40.6% reported unchanged stress during this most challenging preclinical semester. Substantial ceiling effects were seen in study measures. We showed that a tailored executive/life coaching program for first year medical students in the United States is feasible, tolerable, and safe; adherence was excellent. Global utility ratings and willingness to recommend coaching provide substantial support for efficacy. Better measures and larger-scale clinical trial designs are needed for formal proof.

ACS Style

Donna Cameron; Laura J. Dromerick; Jaeil Ahn; Alexander W. Dromerick. Executive/life coaching for first year medical students: a prospective study. BMC Medical Education 2019, 19, 163 .

AMA Style

Donna Cameron, Laura J. Dromerick, Jaeil Ahn, Alexander W. Dromerick. Executive/life coaching for first year medical students: a prospective study. BMC Medical Education. 2019; 19 (1):163.

Chicago/Turabian Style

Donna Cameron; Laura J. Dromerick; Jaeil Ahn; Alexander W. Dromerick. 2019. "Executive/life coaching for first year medical students: a prospective study." BMC Medical Education 19, no. 1: 163.

Journal article
Published: 07 June 2018 in International Journal of Environmental Research and Public Health
Reads 0
Downloads 0

While epidemiologic studies clearly demonstrate drinking water with high levels of arsenic as a significant risk factor for lung cancer, the evidence at low levels (≤50 μg/L) is uncertain. Therefore, we have conducted an ecological analysis of recent lung cancer incidence for US counties with a groundwater supply of <50 μg/L, the historical limit for both the EPA and WHO. Data sources used included USGS for arsenic exposure, NCI for lung cancer outcome, and CDC and US Census Bureau forcovariates. Poisson log-linear models were conducted for male, female, and total populations using for exposure median county arsenic level, maximum arsenic level ≤50 μg/L, and ≥80% population groundwater dependency. Statistically significant negative associations were found in each of the six models in which the exposure was limited to those who had major exposure (≥80% dependency) to low-levels of arsenic (≤50 μg/L). This is the first large ecological study of lung cancer risk from drinking water arsenic levels that specifically examined the dose-response slope for populations whose exposure was below the historical limit of ≤50 μg/L. The models for each of the three populations (total; male; female) demonstrated an association that is both negative and statistically significant.

ACS Style

Steven H. Lamm; Isabella J. Boroje; Hamid Ferdosi; Jaeil Ahn. Lung Cancer Risk and Low (≤50 μg/L) Drinking Water Arsenic Levels for US Counties (2009–2013)—A Negative Association. International Journal of Environmental Research and Public Health 2018, 15, 1200 .

AMA Style

Steven H. Lamm, Isabella J. Boroje, Hamid Ferdosi, Jaeil Ahn. Lung Cancer Risk and Low (≤50 μg/L) Drinking Water Arsenic Levels for US Counties (2009–2013)—A Negative Association. International Journal of Environmental Research and Public Health. 2018; 15 (6):1200.

Chicago/Turabian Style

Steven H. Lamm; Isabella J. Boroje; Hamid Ferdosi; Jaeil Ahn. 2018. "Lung Cancer Risk and Low (≤50 μg/L) Drinking Water Arsenic Levels for US Counties (2009–2013)—A Negative Association." International Journal of Environmental Research and Public Health 15, no. 6: 1200.

Multicenter study
Published: 03 January 2017 in Journal of Neuroinflammation
Reads 0
Downloads 0

Treatment of mild-moderate Alzheimer’s disease (AD) subjects (N = 119) for 52 weeks with the SIRT1 activator resveratrol (up to 1 g by mouth twice daily) attenuates progressive declines in CSF Aβ40 levels and activities of daily living (ADL) scores. For this retrospective study, we examined banked CSF and plasma samples from a subset of AD subjects with CSF Aβ42 <600 ng/ml (biomarker-confirmed AD) at baseline (N = 19 resveratrol-treated and N = 19 placebo-treated). We utilized multiplex Xmap technology to measure markers of neurodegenerative disease and metalloproteinases (MMPs) in parallel in CSF and plasma samples. Compared to the placebo-treated group, at 52 weeks, resveratrol markedly reduced CSF MMP9 and increased macrophage-derived chemokine (MDC), interleukin (IL)-4, and fibroblast growth factor (FGF)-2. Compared to baseline, resveratrol increased plasma MMP10 and decreased IL-12P40, IL12P70, and RANTES. In this subset analysis, resveratrol treatment attenuated declines in mini-mental status examination (MMSE) scores, change in ADL (ADCS-ADL) scores, and CSF Aβ42 levels during the 52-week trial, but did not alter tau levels. Collectively, these data suggest that resveratrol decreases CSF MMP9, modulates neuro-inflammation, and induces adaptive immunity. SIRT1 activation may be a viable target for treatment or prevention of neurodegenerative disorders. ClinicalTrials.gov NCT01504854

ACS Style

Charbel Moussa; Michaeline Hebron; Xu Huang; Jaeil Ahn; Robert A. Rissman; Paul S. Aisen; Raymond Turner. Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease. Journal of Neuroinflammation 2017, 14, 1 -10.

AMA Style

Charbel Moussa, Michaeline Hebron, Xu Huang, Jaeil Ahn, Robert A. Rissman, Paul S. Aisen, Raymond Turner. Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease. Journal of Neuroinflammation. 2017; 14 (1):1-10.

Chicago/Turabian Style

Charbel Moussa; Michaeline Hebron; Xu Huang; Jaeil Ahn; Robert A. Rissman; Paul S. Aisen; Raymond Turner. 2017. "Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease." Journal of Neuroinflammation 14, no. 1: 1-10.

Journal article
Published: 21 September 2016 in Clinical Proteomics
Reads 0
Downloads 0

Non-invasive monitoring of liver disease remains an important health issue. Liver secreted glycoproteins reflect pathophysiological states of the organ and represent a rational target for serologic monitoring. In this study, we describe sialylated O-glycoforms of liver-secreted hemopexin (HPX) and quantify them as a ratio of disialylated to monosialylated form (S-HPX). We measured S-HPX in serum of participants of the HALT-C trial using a LC-MS/MS-MRM assay. Repeated measurements of S-HPX in the samples of 23 disease-free controls, collected at four different time points, show that the ratio remains stable in the healthy controls but increases with the progression of liver disease. The results of measurement of S-HPX in serum of participants of the HALT-C trial show that it increased significantly (Kruskal-Wallis test, p < 0.01) in liver disease as the stage of fibrosis progressed in liver biopsies. We observed a 1.7-fold increase in fibrosis defined as Ishak score 3-4 (24.9 + 14.2, n = 22) and 4.7-fold increase in cirrhosis defined as Ishak score 5-6 (68.6 + 38.5; n = 24) compared to disease-free controls (14.7 + 6.7, n = 23). S-HPX is correlated with AFP, bilirubin, INR, ALT, and AST while inversely correlated with platelet count and albumin. In an independent verification set of samples, S-HPX separated the Ishak 5-6 (n = 15) from the Ishak 3-4 (n = 15) participants with AuROC 0.84; at the same time, the Ishak 3-4 group was separated from disease-free controls (n = 15) with AuROC 0.82. S-HPX, a measure of sialylated O-glycoforms of hemopexin, progressively increases in fibrotic and cirrhotic patient of HCV etiology and can be quantified by an LC-MS/MS-MRM assay in unfractionated serum of patients. Quantification of sialylated O-glycoforms of this liver secreted glycoprotein represents a novel measure of the stage of liver disease that could have a role in monitoring the progression of liver pathology.

ACS Style

Miloslav Sanda; Julius Benicky; Jing Wu; Yiwen Wang; Kepher Makambi; Jaeil Ahn; Coleman I. Smith; Peng Zhao; Lihua Zhang; Radoslav Goldman. Increased sialylation of site specific O-glycoforms of hemopexin in liver disease. Clinical Proteomics 2016, 13, 24 .

AMA Style

Miloslav Sanda, Julius Benicky, Jing Wu, Yiwen Wang, Kepher Makambi, Jaeil Ahn, Coleman I. Smith, Peng Zhao, Lihua Zhang, Radoslav Goldman. Increased sialylation of site specific O-glycoforms of hemopexin in liver disease. Clinical Proteomics. 2016; 13 (1):24.

Chicago/Turabian Style

Miloslav Sanda; Julius Benicky; Jing Wu; Yiwen Wang; Kepher Makambi; Jaeil Ahn; Coleman I. Smith; Peng Zhao; Lihua Zhang; Radoslav Goldman. 2016. "Increased sialylation of site specific O-glycoforms of hemopexin in liver disease." Clinical Proteomics 13, no. 1: 24.